Circulating tumor cells in breast cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Cancer Biomarkers

Background:

• Circulating tumor cell (CTC) measurement in peripheral blood provides prognostic information for breast cancer patients.
• Current CTC detection methods primarily rely on epithelial markers, but circulating DNA measurement is considered more appropriate.
• Micrometastasis may occur early in tumor development, suggesting CTC presence even in non-metastatic settings.

Purpose of the Study:

• To review evidence supporting the prognostic and predictive power of CTCs for clinical utility in breast cancer.
• To explore novel approaches and the role of CTCs in early and metastatic breast cancer.
• To summarize current knowledge on CTCs, including their potential in personalized cancer therapy.

Main Methods:

• Systematic review of 81 manuscripts categorized into discovery datasets, prognostic factors in metastatic breast cancer, clinical utility in early breast cancer, and novel approaches.
• Analysis of CTC marker concordance with primary tumors, including human epidermal growth factor receptor-2 (HER2) status.
• Investigation into the role of microenvironment and potential stimuli for malignant transformation.

Main Results:

• Evidence for the clinical utility of CTCs as prognostic and predictive markers is accumulating.
• Discrepancies in HER2 status between primary tumors and CTCs highlight the need for advanced characterization.
• CTCs numbers can vary with chemotherapy, indicating their dynamic nature during treatment.

Conclusions:

• Genetic profiling and molecular characterization of CTCs can overcome diagnostic challenges.
• CTCs hold significant potential for improving patient stratification and enabling personalized breast cancer therapy.
• Further research into CTCs will enhance their integration into routine clinical practice for better patient outcomes.